TALICIA

At a glance

Key dates

1. Approval

   FDA approval date of this drug product.

   Nov 01, 2019

   6 yr 9 mo ago

2. Exclusivity ends · NP

   New product exclusivity (3 years)

   Nov 01, 2022

   3 yr 8 mo ago

3. Today

4. Exclusivity ends · GAIN

   Qualified infectious disease product exclusivity (adds 5 years)

   Nov 01, 2027

   in 1 yr 5 mo

5. Patent 10238606 expires

   Listed drug product patent expiration.

   Feb 12, 2034

   in 7 yr 9 mo

6. Patent 11135172 expires

   Listed drug product patent expiration.

   Feb 12, 2034

   in 7 yr 9 mo

7. Patent 11931463 expires

   Listed drug product patent expiration.

   Feb 12, 2034

   in 7 yr 9 mo

8. Patent 9050263 expires

   Listed drug product patent expiration.

   Feb 12, 2034

   in 7 yr 9 mo

9. Patent 9498445 expires

   Listed drug product patent expiration.

   Feb 12, 2034

   in 7 yr 9 mo

10. Patent 9603806 expires

    Listed drug product patent expiration.

    Feb 12, 2034

    in 7 yr 9 mo

11. Patent 11878011 expires

    Listed method-of-use patent (U-3816) expiration.

    May 27, 2042

    in 16 yr 2 mo

Pharmaceutical detail

This is a reference-listed drug (RLD) — the basis for generic (ANDA) applications. Other products sharing this ingredient are listed below.

Marketing exclusivity (2)

• NPNew product exclusivity (3 years)

  Nov 01, 2022

  3 yr 8 mo ago

• GAINQualified infectious disease product exclusivity (adds 5 years)

  Nov 01, 2027

  in 1 yr 5 mo

Listed patents (7)